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The accumulation of amyloid β peptide (Aβ) in the brain of Alzheimer’s disease (AD)
patients begins many years before clinical onset. Such process has been proposed
to be pathogenic through the toxicity of Aβ soluble oligomers leading to synaptic
dysfunction, phospho-tau aggregation and neuronal loss. Yet, a massive accumulation
of Aβ can be found in approximately 30% of aged individuals with preserved cognitive
function. Therefore, within the frame of the “amyloid hypothesis”, compensatory
mechanisms and/or additional neurotoxic or protective factors need to be considered
and investigated. Here we describe a modifier genetic screen in Drosophila designed
to identify genes that modulate toxicity of Aβ42 in the CNS. The expression of Aβ42 led
to its accumulation in the brain and a moderate impairment of negative geotaxis at
18 days post-eclosion (d.p.e) as compared with genetic or parental controls. These
flies were mated with a collection of lines carrying chromosomal deletions and negative
geotaxis was assessed at 5 and 18 d.p.e. Our screen is the first to take into account
all of the following features, relevant to sporadic AD: (1) pan-neuronal expression of
wild-type Aβ42; (2) a quantifiable complex behavior; (3) Aβ neurotoxicity associated
with progressive accumulation of the peptide; and (4) improvement or worsening of
climbing ability only evident in aged animals. One hundred and ninety-nine deficiency
(Df) lines accounting for ∼6300 genes were analyzed. Six lines, including the deletion
of 52 Drosophila genes with human orthologs, significantly modified Aβ42 neurotoxicity
in 18-day-old flies. So far, we have validated CG11796 and identified CG17249 as a
strong candidate (whose human orthologs are HPD and PRCC, respectively) by using
RNAi or mutant hemizygous lines. PRCC encodes proline-rich protein PRCC (ppPRCC)
of unknown function associated with papillary renal cell carcinoma. HPD encodes
4-hydroxyphenylpyruvate dioxygenase (HPPD), a key enzyme in tyrosine degradation
whose Df causes autosomal recessive Tyrosinemia type 3, characterized by mental
retardation. Interestingly, lines with a partial Df of HPD ortholog showed increased
Abbreviations: AD, Alzheimer’s disease; Aβ, amlyoid β peptide; Aβ42, amyloid β peptide 1-42; CK, creatine kinases;
Df, deficiency; DIOPT, Drosophila RNAi Screen Center Integrative Ortholog Prediction Tool; dpe, days post-eclosion;
G4, Gal4; H&E, hematoxylin-eosin; HPPD, 4-hydroxy-phenylpyruvate dioxygenase; PBS, phosphate buffered saline; Ppil2,
peptidylprolyl isomerase-like 2; ppPRCC, proline-rich protein PRCC; qRT-PCR, quantitative real-time PCR; RING, Rapid
Iterative Negative Geotaxis; RM, repeated measures; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis;
ThS, thioflavine S; UAS, upstream activating sequence.
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intraneuronal accumulation of Aβ42 that coincided with geotaxis impairment. These
previously undetected modifiers of Aβ42 neurotoxicity in Drosophila warrant further study
to validate their possible role and significance in the pathogenesis of sporadic AD.
Keywords: amyloid β, Alzheimer’s disease, neurodegeneration, genetic screen, Drosophila, dementia
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent form of dementia
in the aged population worldwide and its impact is steadily
growing due to the extension of life expectancy (Cacace et al.,
2016; Scheltens et al., 2016). More than 95% of AD cases are
sporadic, with age and the epsilon 4 allele of the apolipoprotein
E gene as the major risk factors. Rare familial forms are
associated with mutations in the amyloid precursor protein and
presenilin 1–2 genes (Campion et al., 1995; Newman et al.,
2007; Kandimalla et al., 2011, 2012; De Strooper and Karran,
2016).
AD brain is characterized by a pervasive synaptic loss and
the accumulation of protein aggregates mostly composed of
Aβ42 and microtubule-associated protein tau. Oligomeric
species of Aβ42 have been proposed as early pathogenic
molecules by inducing mitochondrial and endoplasmic
reticulum stress, an increase in reactive oxygen species
formation and action potential abnormalities (Karran et al.,
2011; De Strooper and Karran, 2016). AD tau is excessively
phosphorylated and aggregates intracellularly leading to
microtubule instability and organelle failure (Khan and Bloom,
2016). However, the accumulation of Aβ and phospho-tau is not
sufficient for the development of AD. Large autopsy series show
that about 30%–40% of individuals can sustain a normal or nearly
normal cognitive function at a very old age despite extensive
Aβ and phospho-tau pathology (Bennett et al., 2006; Maarouf
et al., 2011; Perez-Nievas et al., 2013). Several hypothesis
have been put forward to explain such clinico-pathological
dissociation, including differences in ‘‘cognitive/brain reserve’’
or the presence of compensatory mechanisms at a functional
or molecular level (Maarouf et al., 2011; Steffener and Stern,
2012). In this context, the search for novel genetic and epigenetic
factors that partake in neurotoxicity mechanisms related
to Aβ is of key importance for understanding the disease
process.
Drosophila is widely used for genetic screens applied to study
the molecular bases of neurodegenerative disorders including
AD (Crowther et al., 2005; Moloney et al., 2010; Lenz et al., 2013;
Prüßing et al., 2013; Shulman et al., 2014; Fernandez-Funez et al.,
2015; Liu et al., 2015). Major advantages of this animal model
include a complex CNS, the fact that about 70% of human genetic
diseases have a Drosophila genetic counterpart (Jackson, 2008;
Bouleau and Tricoire, 2015; Lim et al., 2016) and the availability
of large collections of mutant and transgenic lines.
Forward genetic screens in Drosophila have been used to
identify modifiers of Aβ neurotoxicity. Cao et al. (2008) used
a collection of transgenic lines carrying directionally inserted
P elements and screened for enhancers or suppressors of a
rough eye phenotype induced by Aβ42. In this way, they
identified candidate genes involved in cellular processes such
as transcription regulation, proteolysis in the secretory pathway
and cholesterol metabolism (Finelli et al., 2004; Cao et al.,
2008). By screening a collection of chromosomal deletions, the
same group found that the toll-NFκB pathway enhanced both
Aβ-induced rough eye and a negative effect upon life span (Tan
et al., 2008). Rival et al. (2009) screened 3000 lines carrying
P element inserts for modifiers of a shorter life span induced
by the ‘‘Arctic’’ variant of Aβ42 (AβE22G) associated with
familial AD. Notably, they found that genes associated with
redox or antioxidant activities were strong modifiers of AβE22G
neurotoxicity (Rival et al., 2009). By inducing misexpression
of genes involved in specific developmental pathways, several
modifiers of Aβ42 toxicity upon photoreceptors have been
described (Moran et al., 2013). In addition to the eye phenotype
and life span, the gravitaxis behavior (negative geotaxis) can be
used for genetic screening. This test provides easily quantifiable
data, explores a complex behavior of the Drosophila CNS
and allows a rapid assessment of age-dependent Aβ toxicity.
Recently, Liu et al. (2015) developed an automatic device for the
Rapid Iterative Negative Geotaxis (RING) assay and screened a
collection of chromosomal deletions to findmodifiers of AβE22G
neurotoxicity upon the giant fiber system neurons (Gargano
et al., 2005; Liu et al., 2015).
The aim of the present study was to develop a modifier
screen designed to study the effect of chromosomal deletions
upon neuronal toxicity mediated by pan-neural expression
of wild-type Aβ42 in the CNS (the major isoform that
accumulates in the brain of sporadic AD patients). Fly
lines with defined genomic deletions were found to exert a
dominant effect under the presence of Aβ42. Deficiency (Df)
lines that significantly enhanced age-dependent Aβ42 toxicity
included CG17249 and CG11796 whose human orthologs
are PRCC and HPD, respectively. PRCC encodes proline-rich
protein PRCC (ppPRCC), a protein of unknown function
associated with renal cell carcinomas. HPD encodes 4-hydroxy-
phenylpyruvate dioxygenase (HPPD), a key enzyme in tyrosine
degradation.
MATERIALS AND METHODS
Fly Stocks
Flies were raised at 25◦C in a standard cornmeal with a light:dark
cycle of 12 h:12 h. The line expressing Aβ1-42 fused with
the rat pre-proenkephalin signal peptide was kindly provided
by Dr. Mary Konsolaki (Rutgers University). The upstream
activating sequence (UAS)-Aβ42 construct is inserted in the 2nd
chromosome. Lines w1118 #5905 (+), elavc155 [Gal4] #458 (G4),
lines from the Df kit and the mutants for CG11796 #51528 and
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CG17249 #16098 were obtained from Bloomington Drosophila
Stock Center (NIH P0OD018537). The CG11796 RNAi line
#103482 was obtained fromVDRC Stock Center. The elav [Gal4];
[UAS] Aβ42/Cyo line (G4 > Aβ42) was generated for the
screen.
RING Assay
Groups of 30–40 male flies were raised at 25◦C in 4-inch
glass vials with food replacement every 2–3 days. The geotaxis
behavior was tested using the RING assay as described (Gargano
et al., 2005). The day before the test, 10 flies were shortly
anesthetized with CO2 and placed into a fresh vial. They were
let to recover overnight at 25◦C, transferred to clear glass vials
and placed them in the negative geotaxis device. The device was
tapped three times in rapid succession to initiate the response
and climbing was recorded for 10 s. The climbed distance in
cm was measured for each fly and the average height from five
technical replicates per genotype was calculated using the Scion
Image software.
SDS-PAGE and Western Blots
Forty heads from 5 to 18-day-old flies were homogenized in
60 µl of RIPA buffer, pH 7.4, containing 1% SDS, 5 mM EDTA,
5 mM EGTA, 1 mM PMSF, 0.5 µg/ml leupeptin, 0.5 µg/ml
aprotinin, 1 mg/ml pepstatin and 50 mM NaF. Homogenates
were centrifuged at 10,000× g for 1 h at 4◦C. Twenty µl
of the supernatant containing ∼150 µg of total proteins,
were resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in a 12.5% Tris-tricine gel. After
transfer to polyvinylidene fluoride membranes, proteins were
analyzed by Western blot. Aβ42 was detected with anti-Aβ
monoclonal 6E10 (Biolegend Co.) used at 1:1000. Actin was
detected with rabbit polyclonal anti-actin (Sigma) at 1:1000. After
washing with PBS-T, membranes were incubated anti-rabbit
or anti-mouse horseradish peroxidase-labeled IgGs (Dako,
Denmark) at 1:10000. Immunoreactivity was visualized by
chemiluminescence with ECL Prime (GE Bioscience, Piscataway,
NJ, USA) and scanned with an Image Quant LAS 4000 apparatus
(GE Bioscience, Piscataway, NJ, USA). For relative quantitation,
optical densities from each lane were obtained and analyzed
with the ImageJ software. Synthetic Aβ1-42 was obtained from
American Peptide Co.
Inmunohistochemistry and Thioflavin S
Staining
Adult heads were fixed with 4% paraformaldehyde in phosphate
buffered saline (PBS) for 45 min at room temperature (RT).
Fly brains were dissected in PBS containing 0.1% Triton X-100
(PT). Brains were blocked in 10% normal goat serum for 1 h
in PT and incubated with antibody 6E10 at 4◦C overnight.
After incubation with Cy3-labeled anti-mouse antibody (Jackson
InmunoResearch, West Grove, PA, USA) for 2 h at RT,
brain tissue was stained with DAPI, washed with PBS and
mounted in PBS containing 80% glycerol. For amyloid fibril
staining, brains were incubated in 50% ethanol containing
1% thioflavine S (ThS; Sigma, St.Louis, MO, USA) overnight
at 4◦C. Samples were washed with PBS containing 50%
ethanol and mounted in 80% glycerol. Brain samples from a
transgenic mouse carrying the ‘‘Swedish’’ mutation of amyloid
precursor protein (Tg2576) were used as positive controls.
Images were captured with a Zeiss LSM 510 Meta Confocal
microscope.
Histology and Vacuolization Assessment
Fly heads were fixed overnight in Carnoy solution (60% ethanol,
30% chloroform, 10% acetic acid) at 4◦C and dehydrated in
increasing concentrations of ethanol. Then, they were treated
with butanol:ethanol (1:1), butanol:toluene (1:1) and toluene
30 min each, and finally soaked in toluene:paraffin (1:1) for
30 min at 65◦C. After a 2-h incubation at 65◦C in pure paraffin,
heads were embedded and cut in 8 µm serial frontal sections.
After H&E staining, images were captured using an OLYMPUS
B× 50 Microscope and analyzed with the ImageJ software. Brain
tissue loss was quantified as described (Sarantseva et al., 2009).
The area occupied by vacuoles with a diameter of at least 3 µm
was divided by the total area of the section and expressed as
percentage of area loss. At least eight brains per genotype were
analyzed.
Genetic Screen
To perform the genetic screen, the G4 > Aβ42 line was mated
with Df lines from the Bloomington Df kit (Cook et al., 2012;
Cook, 2016) to generate elavc155 [Gal4]; [UAS] Aβ42/+> Df/+
(G4 > Aβ42/Df). The experimental design consisted of three
stages (Figure 1). In stage I, G4 > Aβ42/Df lines were analyzed
at 5 and 18 days post-eclosion (d.p.e) to find a modified
phenotype as compared to G4>Aβ42. Genetic controls included
G4>+ and +>Aβ42. Those Df lines that showed a difference
of at least 50% in negative geotaxis only at 18 d.p.e in a
single biological experiment were selected. In stage II, each
chromosomal deletion; elavc155 [Gal4]; Df/+ (G4 > Df) was
assessed to rule out that it did not affect negative geotaxis in
the absence of Aβ42 expression. Three independent biological
experiments were performed comparing G4 > Aβ42 with
G4 > Aβ42/Df to select the Df lines that reached statistical
significance. Deleted genes were queried for the identification of
human orthologs with expression in the adult CNS (see below).
If the deletion was large and included more than 10 human
orthologs, overlapping deletions were analyzed as in stage II
to reduce the number of candidates. Deletions with less than
10 human orthologs were selected for analysis with RNAi or
mutant lines in stage III.
Bioinformatic Analysis of Deficiency Lines
Genomic deletions were queried in Bloomington Stock web
page1. The corresponding gene list was obtained from FlyBase2
(Attrill et al., 2016) using the GBrowse function and the Hit
List tool. Each gene was searched for its human ortholog with
the highest weighted score using the Drosophila RNAi Screen
Center (DRSC) Integrative Ortholog Prediction Tool (DIOPT)
1http://www.flystocks.bio.indiana.edu/Browse/df/dfkit.php
2http://www.flybase.org
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FIGURE 1 | Flow chart illustrating the overall strategy and steps of the
modifier genetic screen. In stage I, G4 > amyloid β peptide 1-42 (Aβ42) line
was compared to each of the G4 > Aβ42/Deficiency (Df) lines in a single
negative geotaxis experiment. ∗ In stage II, those G4 > Aβ/Df lines selected in
stage I were examined in three independent biological experiments for
statistical significance at 18 days post eclosion (d.p.e), (one-way ANOVA
followed by least significant difference (LSD) Fisher’s test p < 0.05). ∗∗Human
orthologs were defined as those with the highest score according to
Drosophila RNAi Screen Center (DRSC) integrative ortholog prediction tool
(DIOPT). Depending on the number of deleted orthologs (> or ≤ 10), Df lines
were selected for stage III or back to stage II analysis with overlapping
deletions to narrow down the number of candidates (∗∗∗Overlapping deletions
were compared in three independent biological experiments).
from the DRSC3. Fly gene expression was searched in NCBI
web page4 and the RNA-seq Profile provided by FlyBase on
the gene query subtitle expression data5. Gene products, their
known functions, patterns of expression in humans, protein-
protein interactions and association with human diseases
were obtained from UNIPROT6, Genecards7 and OMIM8
databases.
Preparation of cDNA Samples and
Quantitative Real-Time PCR
RNA from 35 fly heads was extracted with the TriZol reagent
(Invitrogen) according to manufacturer’s instructions. cDNA
was generated from 3 µg of RNA, previously treated with
DNAse (Promega) using the SuperScript III system (Invitrogen).
SYBR-Green quantitative real-time PCR (qRT-PCR) was
performed using KAPA SYBR_FAST Universal 2X qPCRMaster
Mix. Reactions were run in a StratageneMx3005P cycler (Agilent
Technologies) and analyzed by the calibration curve method.
For CG11796 primers 5′AAAGGAACCAAACCTGAA GC 3′
3http://www.flyrnai.org/cgi-bin/DRSC_orthologs.pl
4http://www.ncbi.nlm.nih.gov/gene
5http://flybase.org/reports/FBgn0036992.html
6http://www.uniprot.org/
7http://www.genecards.org/
8http://www.omim.org/
(forward) and 5′ATCCCTGATAGCCAAGTGGT 3′ (reverse)
were used. RPL32 was amplified for normalization using the
following primers: 5′ATGCTAAGCTGTCGCACA AATG 3′
(forward) and 5′GTTCGATCCGTAACCGATGT 3′ (reverse).
Statistical Analysis
Results are presented as the mean ± SEM of at least three
independent biological experiments unless otherwise stated. Data
were analyzed by repeated measures (RM) two-way ANOVA
with post hoc Bonferroni’s test, RM one-way ANOVA followed
by Least Significant Difference (LSD) Fisher’s test or Student’s
t test using the Prismr Graphpad 6 software. Wilcoxon
non-parametric test were used when indicated. The level of
significance was set at p< 0.05.
RESULTS
G4 > Aβ42 Line Shows a Moderate and
Age-Dependent Toxic Phenotype
A transgenic line with constitutive, pan-neuronal expression
of Aβ42 maintained at 25◦C was examined as a candidate for
the screen. Western blots of fly head homogenates showed a
∼4.5 kDa band consistent with detergent-soluble Aβ42 correctly
targeted and cleaved in the secretory pathway. A minor band
consistent with SDS-resistant Aβ42 oligomers was also seen.
Between 5 and 18 d.p.e there was a robust 3-fold increase
of Aβ42 levels (Figures 2A,B). Negative geotaxis was not
impaired in 5-day-old flies as compared with controls, strongly
suggesting that there were no developmental effects upon the
CNS due to Aβ42 expression. In 18-day-old flies, a significant
decrease in climbing ability (∼50%) was apparent only in Aβ42-
expressing animals as compared to genetic controls, G4>+
and +>Aβ42 (Figure 2C). Microscopic examination of the
brains of affected flies revealed very mild vacuolization and
negative ThS staining (see below). Therefore, this line showed
age-dependent Aβ42 accumulation and CNS neurotoxicity,
and the magnitude of the functional decline was optimal
for the search of enhancers and suppressors. In addition,
the accretion of non-fibrillar Aβ42 suggests that toxicity was
induced by soluble oligomers, as proposed for AD. Taken
together, these features and experimental conditions made this
Aβ42 transgenic line highly suitable for a forward genetic
screen.
Identification of Df Lines that Modify
Age-Dependent Aβ42 Toxicity
One hundred and ninety-nine lines with defined deletions
from the 2nd, 3rd and 4th chromosomes, accounting for
approximately 6300 genes, were tested in the first stage
of the screen. Negative geotaxis of G4 > Aβ42 line was
compared to G4 > Aβ42/Df lines at 5 and 18 d.p.e. Figure 3
shows actual examples of the three possible outcomes: Df
29667 had no modifying effect, Df 27917 worsened and Df
7681 rescued Aβ42-induced climbing dysfunction. At this stage,
73 G4 > Aβ42/Df lines showed a difference in climbing
ability of at least 50% when compared to G4 > Aβ42 and
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FIGURE 2 | (A) Representative Western blot of fly brain homogenates at 5 and 18 d.p.e showing Aβ42 expression detected with anti-Aβ monoclonal antibody 6E10.
The 4.5 kDa band (arrow) indicates Aβ42 correctly processed in the secretory pathway. The arrowhead indicates a band consistent with sodium dodecyl sulfate
(SDS)-resistant Aβ42 oligomers. A G4>+ brain homogenate was spiked with synthetic Aβ1-42 (Aβ42 Synt.) for electrophoretic mobility control. Membrane was cut
above the 31 kDa marker and probed with anti-actin for normalization. (B) Quantification of Aβ42 levels relative to actin in arbitrary units (A.U.). Bars represent the
mean ± SEM from three independent experiments; ∗∗p < 0.01 (Student’s t-test). (C) Pan-neuronal Aβ42-expressing flies (G4 > Aβ42) showed climbing impairment
at 18 d.p.e as compared with genetic controls (G4>+ and +>Aβ42). Bars represent the mean ± SEM from at least three independent biological experiments;
∗∗∗p < 0.001 (repeated measures [RM] two-way ANOVA followed by Bonferroni’s post hoc test).
such differences were only seen in aged animals. These lines
were selected and analyzed in stage II and six lines met
statistical criteria to be considered as positive hits. Df lines
24392, 27369, 27372, 27404 and 27917 worsened negative
geotaxis while line 7681 reduced Aβ42 toxicity to a full
rescue of the phenotype (Figure 4). In the absence of
Aβ42 expression, Df lines showed no intrinsic effect and none
of the enhancer Df lines induced climbing impairment in
G4 > Aβ42 line at 5 d.p.e, ruling out a possible acceleration
of Aβ42 toxicity (not shown). Within these six Df lines,
36 Drosophila genes with human orthologs remain to be
tested to identify enhancers and 14 genes to pin point
suppressors of Aβ42 neurotoxicity. Interestingly, 14 out of
15 enhancer and six out of seven suppressor Df lines described
in a previous screen based on negative geotaxis (Liu et al.,
2015) were selected in stage I of our screen but did not
reach statistical significance in stage II and were not further
analyzed.
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FIGURE 3 | Negative geotaxis assay of G4 > Aβ42 compared to
G4 > Aβ42/Df at 5 and 18 d.p.e. The graphic shows examples of the three
possible outcomes according to the quantitative criterion of at least a 50%
difference in negative geotaxis (dashed lines): Df 29667 had no modifier effect,
Df 27917 worsened and Df 7681 improved the climbing ability of
Aβ42-expressing flies at 18 d.p.e. Bars represent the mean ± SEM from a
single biological experiment (five technical repeats) and therefore, at this stage
of the screen, no statistical analyses were performed.
Specific Reduction of CG11796 Expression
Enhances Aβ42 Toxicity
Thus far, three out of the five enhancer Df lines that passed
stage II have been partially analyzed in stage III. The enhancer
Df line 27372 included the deletion of CG17249 whose human
ortholog is PRCC. We used a line carrying a Piggy Bac transposon
in the 3′ region of CG17249 to assess toxicity. A significant
enhancement in Aβ42 neurotoxicity was observed in mutant
hemizygous flies (Figure 5A). Although unlikely, the 3′ insertion
may compromise the expression of neighboring genes and
therefore, RNAi experiments are required to validate CG17249.
Df lines 27917 and 27369 also worsened negative geotaxis in the
presence of Aβ42 and the overlapping chromosomal segment
included CG11796 whose human ortholog is HPD encoding
HPPD, a key enzyme involved in tyrosine catabolism. To
determine if a reduced expression of CG11796 was capable of
enhancing Aβ42 toxicity, we used two independent approaches:
a mutant line in which a Mi[Mic] transposon was inserted
in the CG11796 gene and a specific RNAi with pan-neuronal
expression using the elav promoter. These lines had no
impairment in negative geotaxis as compared with control flies
despite the reduction of CG11796 mRNA. Yet, in the presence
of pan-neuronal Aβ42 expression, CG11796 downregulation
in both the RNAi and mutant lines induced a significant
enhancement of Aβ42 toxicity, similar to the overall effect of
the chromosomal deletions detected at stages I-II of the screen
(Figures 5B,C). The specificity of the RNAi was assessed by
qRT-PCR from fly heads, which showed a strong reduction of
CG11796 mRNA of approximately 85% in G4 > CG11796RNAi
and 55% in CG11796Mut, similar to the expected ∼50% mRNA
reduction in Df line 27917 (Figure 5D).
Reduction of CG11796 Expression
Promotes the Accumulation of
Non-Fibrillar Aβ42
Aβ42 levels were analyzed in the brains of flies with partial
Df of CG11796 at 18 days of age, when the toxic phenotype
was detected. Confocal immunofluorescence showed extensive
intraneuronal perinuclear Aβ accumulation which was ∼2-fold
higher in both CG11796 hemizygous mutant and CG11796RNAi
as compared with flies expressing Aβ42 alone (Figure 6).
Western blots of head homogenates showed a 70%–80%
increase in the Aβ monomer band in CG11796 mutant
and RNAi lines, consistent with the immunofluorescence
results (Figure 7). The increment of Aβ abundance was
not accompanied by ThS staining, indicating that a partial
Df of CG11796 expression promoted the accumulation of
non-fibrillar Aβ species (Figure 8). Instead, the pattern of
immunostaining and detergent solubility suggest the accretion
of intraneuronal oligomeric Aβ which concurs with a higher
neurotoxicity in CG11796Mut and CG11796RNAi flies. To assess
neurodegeneration further, the extent of vacuolization in the
brain was determined for each genotype. As mentioned above,
there was a mild though significant increase of vacuolization in
flies expressing Aβ42 as compared with their genetic controls.
Yet, tissue loss did not increase in Aβ42-transgenic flies
expressing CG11796mutant or RNAi (Figure 9). Together, these
results strongly suggest that a partial Df of the HPD ortholog
promotes the accumulation of toxic Aβ42 oligomers in the CNS
leading to cellular dysfunction without histologically detectable
neuronal loss.
DISCUSSION
The finding of proteins that modulate Aβ neurotoxicity in
animals with a complex CNS such as Drosophila may impact on
AD research in several ways. First, by providing novel players
in the cellular mechanisms by which Aβ promotes synaptic
dysfunction and neuronal death. Second, changes in the levels
or activity of those proteins may be validated in human samples
including post-mortem tissue and, more relevant, in biological
fluids as potential biomarkers. Third, in the long range, it may
open therapeutic strategies alternative to the current ones mostly
aimed at Aβ and tau. Previous modifier screens in the fly
have yielded interesting candidates that modulate wild-type Aβ
toxicity in the eye, upon life span, or negative geotaxis induced by
an aggressive Aβ mutant (Cao et al., 2008; Tan et al., 2008; Rival
et al., 2009; Liu et al., 2015). Our screen was designed to search
for modifiers in a context of neurotoxicity more related to what
may occur in sporadic AD, including pan-neuronal expression
of wild-type Aβ42 and age-dependent accumulation with no
detectable behavioral impairment in young animals. Moreover,
the Aβ42 transgenic line had a rather mild phenotype at
∼3 weeks of age, with little neuronal loss and the accumulation of
detergent-soluble, non-fibrillar species of Aβ, avoiding features
that are found in late stages of AD.
The discrepancies between our results and those reported
by Liu et al. (2015) may be due to criteria for defining
positive hits and the use in their study of AβE22G driven to
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FIGURE 4 | Negative geotaxis assay of G4>+, G4 > Aβ42, G4 > Aβ42/Df and G4 > Df at 18 d.p.e. (A) Df 24392; (B) Df 27369; (C) Df 27372; (D) Df 27404;
and (E) Df 27917, worsened the Aβ42-induced phenotype. (F) Df 7681 improved the climbing ability of Aβ42-expressing flies. Df lines had no effect in the absence of
Aβ expression. Bars represent the mean ± SEM from at least three independent biological experiments; ∗p < 0.5, ∗∗p < 0.01, ∗∗∗p < 0.001 (RM one-way ANOVA
followed by LSD Fisher’s test).
specific interneurons that relay to thoracic muscles instead of
pan-neuronal wild-type Aβ42. Noteworthy, in both studies Df
line 7681 was a strong suppressor, suggesting that one or more
genes in homozygosity within this deletion are necessary for Aβ
to impair geotaxis behavior, independent of Aβ species and type
of neurons involved.
A limitation of our study was its restriction to the effect of
gene deletions and therefore, likely dependent on lower than
physiological levels of the encoded proteins. Those genes that
modulate Aβ42 toxicity through overexpression would be missed
with our strategy.
So far, two genes have passed stage III of our screen whose
human orthologs are PRCC and HPD. While PRCC requires
a final validation step with RNAi, HPD was unambiguously
identified. The function of ppPRCC is largely unknown although
early studies suggest that it may have a role in pre-mRNA
splicing (Skalsky et al., 2001). A search for ppPRCC protein-
protein interactions revealed association with peptidylprolyl
isomerase-like 2 (Ppil2), a chaperone with putative ubiquitin
ligase activity (Hatakeyama et al., 2001; Pushkarsky et al., 2005;
Hegele et al., 2012). Thus, a possible role of a ppPRCC-Ppil-2
complex in protein folding, transport and degradation warrants
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FIGURE 5 | Mutants and RNAi of candidate genes enhance Aβ toxicity. (A) CG17249 hemizygous mutant (human ortholog, PRCC); (B) CG11796 hemizygous
mutant (human ortholog, HPD) and (C) CG11796 RNAi. Mutant and RNAi lines had no effect in the absence of Aβ42 expression. Bars represent mean ± SEM from
at least three independent biological experiments; ∗p < 0.5; ∗∗p < 0.01; ∗∗∗p < 0.001 (one-way ANOVA followed by LSD Fisher’s test). (D) Quantification of
CG11796 endogenous mRNA showed a ∼40%–50% reduction in Df 27917 and CG11796Mut lines, while for CG11796RNAi a ∼ 85% reduction was observed. Brain
samples were taken from 5 day-old flies and RPL32 mRNA was used for normalization in each quantitative real-time PCR (qRT-PCR) assay. ∗∗∗p < 0.001 for
Df 27917, CG11796Mut and CG11796RNAi as compared to G4>+. ∗p < 0.05 (RM one-way ANOVA followed by LSD Fisher’s test from three independent biological
experiments).
further study in the context of Aβ neurotoxicity. HPD encodes
a highly conserved protein that catalyzes the conversion of
4-hydroxyphenylpyruvate to homogentisate, the second step in
the tyrosine degradation pathway. Mutations in HPD cause the
rare diseases Tyrosinemia type 3 and Hawkinsiuria. Tyrosinemia
type 3 is autosomal recessive; patients show mental retardation
and elevated levels of tyrosine and its derivatives in blood and
urine due to HPPD Df (reviewed in Scott, 2006). Hawkinsinuria
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FIGURE 6 | Immunofluorescence of Aβ deposits in the brains of transgenic lines. (A) Representative image of a brain section at low magnification stained
with DAPI. The red square depicts the region used for quantification in each genotype. Scale bar = 100 µm. (B) Representative images of the selected region as in
panel (A) showing from left to right: anti-Aβ, DAPI nuclear staining and the merge of both signals. Scale bar = 10 µm. Genotypes G4 > Aβ42,
G4 > Aβ42/CG11796Mut and G4 > Aβ42/CG11796 RNAi are shown. (C) Quantification of Aβ fluorescence intensity normalized to G4 > Aβ42 in A.U. showing the
increment induced by CG11796 mRNA reduction. Bars represent the mean-ratio ± SEM of three independent experiments; ∗p < 0.05 (Wilcoxon test).
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FIGURE 7 | Western blot of Aβ accumulation in the brain of CG11796 RNAi and mutant lines. (A) Representative Western blot of fly brain homogenates in
RIPA buffer at 18 d.p.e showing Aβ42 expression detected with monoclonal antibody 6E10. The arrow indicates Aβ42 monomers. Membranes were cut above the
31 kDa marker and probed with anti-actin for normalization. (B) Quantification of Aβ42 levels relative to actin in A.U. normalized to G4 > Aβ42 showing the increase
of Aβ42 in CG11796 mutant and RNAi lines. Bars represent the mean-ratio ± SEM of three independent experiments; ∗p < 0.05 (Wilcoxon test).
FIGURE 8 | Negative thioflavine S (ThS) staining of Aβ42 transgenic flies brains. (A–C) Representative images of ThS staining of fly brains at 18 d.p.e from
G4 > Aβ42, G4 > Aβ42/CG11796Mut and G4 > Aβ42/CG11796RNAi showing no detection of amyloid fibrils. Scale bar = 100 µm. (D) A brain section of transgenic
mouse Tg2576 showing ThS-positive plaques (arrows) is shown for comparison. Scale bar = 500 µm.
is autosomal dominant and characterized by metabolic acidosis
and urinary excretion of ‘‘hawkinsin’’, a cyclic amino acid
derived from quinolacetic acid produced by mutant HPPD
(Brownlee et al., 2010). The mechanisms underlying mental
retardation in Tyrosinemia are not known, yet an increase of
acetylcholinesterase activity and energy metabolic impairment
have been postulated (Ferreira et al., 2012, 2015). In addition,
high tyrosine levels may reduce the activity of thiol-dependent
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FIGURE 9 | Brain vacuolization in Aβ-expressing lines alone and in a background of CG11796 Df. (A) Representative whole brain section of G4>+ stained
with H&E used for tissue loss analysis by bright-field microscopy. The rectangle demarcates a typical area with a high number of neuronal bodies. (B) The region
depicted in (A) is shown for each genotype. Arrows indicate vacuoles with a diameter of at least 3 µm. Scale bar = 50 µm. (C) Quantification of tissue loss in
hemi-brains was calculated as the percentage of the section area occupied by vacuoles. Flies expressing Aβ42 showed increased vacuolization as compared to
control flies G4>+. No differences were found in G4 > Aβ42/CG11796Mut and G4 > Aβ42/CG11796RNAi compared with G4 > Aβ42. ∗∗∗p < 0.001 (one way ANOVA
followed by Tukey’s post hoc test).
creatine kinases (CK) leading to misbalance of a key ATP
buffering and shuttling system (Wallimann et al., 2011; de
Andrade et al., 2012). Interestingly, CK activity is reduced in AD
brains as compared to age-matched controls and Aβ induces a
reduction of CK activity in cultured neurons (Aksenov et al.,
1998, 2000; David et al., 1998). Consistent with these findings,
creatine accumulates in old transgenic mice expressing a mutant
APP and in the hippocampus of ADpatients (Gallant et al., 2006).
Our finding that the partial Df of HPD ortholog promoted the
accumulation of oligomeric Aβ42 provides a likely explanation
for the worsening of age-dependent geotaxis performance. Yet,
such degree of Aβ accumulation seems to be sufficient to
impact negatively upon neuronal function without inducing
gross neuropathological changes up to 18 d.p.e. With regard to
possible mechanisms for Aβ accretion in the context of lower
HPPD expression, the reduction in CK activity as a consequence
of high tyrosine levels may accelerate Aβ aggregation or impair
its clearance due to lower ATP availability and oxidative stress
(Meyer et al., 2006). Moreover, Aβ42 oligomers induce oxidative
stress (Butterfield et al., 2013) leading to a vicious cycle in disease
progression. Alternatively, the possibility that a partial Df of
HPPD is more directly involved in Aβ accumulation deserves
further investigation. Inhibitors of HPPD such as nitisinone are
used to treat patients with hereditary Tyrosinemia type 1 in
which downstream metabolites of HPPD activity accumulate
and are highly toxic to the kidney and liver (Mayorandan
et al., 2014; Zeybek et al., 2015). Long-term outcome of patients
under nitisinone treatment show a high frequency of progressive
cognitive impairment that has been related with chronically
elevated tyrosine levels (Masurel-Paulet et al., 2008; Thimm et al.,
2012). Early reports on tyrosine levels in the cerebrospinal fluid
of AD as compared with controls remain controversial (Degrell
et al., 1989; Martinez et al., 1993) and there are no studies on
the levels and/or activity of HPPD in AD. In light of our results
regarding Aβ accumulation, such studies may be relevant to
better understand the complex pathogenesis of AD.
In summary, our work describes the first genetic screen to
search for modifiers of wild-type Aβ42 neurotoxicity in the
CNS of Drosophila by exploring age-dependent alterations in
a complex behavior. So far, this strategy has led us to identify
candidate genes that warrant further research to determine their
significance in sporadic AD.
Frontiers in Aging Neuroscience | www.frontiersin.org 11 March 2017 | Volume 9 | Article 61
Belfiori-Carrasco et al. Genetic Screen for Aβ Modifiers
AUTHOR CONTRIBUTIONS
LFB-C, MSM and NIB performed the experiments, analyzed
results, drafted and revised the manuscript; MFC and LM
designed the work, analyzed data, interpreted the results and
revised the manuscript. EMC designed the work, analyzed data,
interpreted the results and wrote the article.
FUNDING
This work was supported by grants from the Alzheimer’s
Association (IIRG 11-205127 to EMC), Agencia Nacional de
Promoción Científica y Tecnológica (ANPCyT) PICT2013-0318
(to EMC), PICT2013-1382 (to MFC) and CONICET-PIP0378
(to LM).
ACKNOWLEDGMENTS
We thank Cecilia Rotondaro, Agata Fernández-Gamba and
Luciana Pujol Lereis for their contributions to this work.
Aβ42 transgenic fly was kindly provided by Dr. Mary Konsolaki
(Rutgers University). Bloomington Drosophila Stock Center and
the Vienna Drosophila RNAi Center provided the flies stocks.
LFB-C fellowship is supported by ANPCyT; MSM and NIB
fellowships are supported by CONICET. MFC, LM and EMC are
Principal Investigators supported by CONICET.
REFERENCES
Aksenov, M., Aksenova, M., Butterfield, D. A., and Markesbery, W. R. (2000).
Oxidative modification of creatine kinase BB in Alzheimer’s disease brain.
J. Neurochem. 74, 2520–2527. doi: 10.1046/j.1471-4159.2000.0742520.x
Aksenov,M. Y., Aksenova,M. V.,Markesbery,W. R., and Butterfield, D. A. (1998).
Amyloid β-peptide (1–40)-mediated oxidative stress in cultured hippocampal
neurons. Protein carbonyl formation, CK BB expression and the level of Cu,
Zn and Mn SOD mRNA. J. Mol. Neurosci. 10, 181–192. doi: 10.1007/bf027
61773
Attrill, H., Falls, K., Goodman, J. L., Millburn, G. H., Antonazzo, G., Rey, A. J.,
et al. (2016). FlyBase: establishing a gene group resource for Drosophila
melanogaster. Nucl. Acids Res. 44, D786–D792. doi: 10.1093/nar/gkv1046
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T.,
Shah, R. C., et al. (2006). Neuropathology of older persons without cognitive
impairment from two community-based studies. Neurology 66, 1837–1844.
doi: 10.1212/01.WNL.0000219668.47116.e6
Bouleau, S., and Tricoire, H. (2015). Drosophila models of Alzheimer’s
disease: advances, limits and perspectives. J. Alzheimers Dis. 45, 1015–1038.
doi: 10.3233/JAD-142802
Brownlee, J. M., Heinz, B., Bates, J., and Moran, G. R. (2010). Product analysis and
inhibition studies of a causative Asn to Ser variant of 4-hydroxyphenylpyruvate
dioxygenase suggest a simple route to the treatment of Hawkinsinuria.
Biochemistry 49, 7218–7226. doi: 10.1021/bi1008112
Butterfield, D. A., Swomley, A. M., and Sultana, R. (2013). Amyloid
β-peptide (1–42)-induced oxidative stress in Alzheimer disease: importance
in disease pathogenesis and progression. Antioxid. Redox Signal. 19, 823–835.
doi: 10.1089/ars.2012.5027
Cacace, R., Sleegers, K., and Broeckhoven, C. V. (2016). Molecular genetics
of early-onset alzheimer disease revisited. Alzheimers Dement. 12, 733–748.
doi: 10.1016/j.jalz.2016.01.012
Campion, D., Flaman, J. M., Brice, A., Hannequin, D., Dubois, B., Martin, C.,
et al. (1995). Mutations of the presenilin I gene in families with early-
onset alzheimer’s disease.Hum. Mol. Genet. 4, 2373–2377. doi: 10.1093/hmg/4.
12.2373
Cao, W., Song, H.-J., Gangi, T., Kelkar, A., Antani, I., Garza, D., et al.
(2008). Identification of novel genes that modify phenotypes induced by
Alzheimer’s β-amyloid overexpression in Drosophila. Genetics 178, 1457–1471.
doi: 10.1534/genetics.107.078394
Cook, K. (2016). Bloomington Drosophila Stock Center at Indiana University.
Bloomington: Indiana University. Available online at: http://flystocks.bio.
indiana.edu/Browse/df/dfkit.php. [Accessed on May 13, 2016].
Cook, R. K., Christensen, S. J., Deal, J. A., Coburn, R. A., Deal, M. E., Gresens, J. M.,
et al. (2012). The generation of chromosomal deletions to provide extensive
coverage and subdivision of theDrosophilamelanogaster genome.Genome Biol.
13:R21. doi: 10.1186/gb-2012-13-3-r21
Crowther, D. C., Kinghorn, K. J., Miranda, E., Page, R., Curry, J. A.,
Duthie, F. A. I., et al. (2005). Intraneuronal Aβ, non-amyloid aggregates and
neurodegeneration in a Drosophilamodel of Alzheimer’s disease. Neuroscience
132, 123–135. doi: 10.1016/j.neuroscience.2004.12.025
David, S., Shoemaker, M., and Haley, B. E. (1998). Abnormal properties
of creatine kinase in Alzheimer’s disease brain: correlation of reduced
enzyme activity and active site photolabeling with aberrant cytosol-membrane
partitioning. Brain. Res. Mol. 54, 276–287. doi: 10.1016/s0169-328x(97)
00343-4
de Andrade, R. B., Gemelli, T., Rojas, D. B., Funchal, C., Dutra-Filho, C. S.,
Wannmacher, C. M., et al. (2012). Tyrosine impairs enzymes of energy
metabolism in cerebral cortex of rats. Mol. Cell. Biochem. 364, 253–261.
doi: 10.1007/s11010-012-1225-y
De Strooper, B., and Karran, E. (2016). The cellular phase of Alzheimer’s disease.
Cell. 164, 603–615. doi: 10.1016/j.cell.2015.12.056
Degrell, I., Hellsing, K., Nagy, E., and Niklasson, F. (1989). Amino acid
concentrations in cerebrospinal fluid in presenile and senile dementia of
Alzheimer type and multi-infarct dementia. Arch. Gerontol. Geriatr. 9,
123–135. doi: 10.1016/0167-4943(89)90033-2
Fernandez-Funez, P., de Mena, L., and Rincon-Limas, D. E. (2015). Modeling
the complex pathology of Alzheimer’s disease in Drosophila. Exp. Neurol. 274,
58–71. doi: 10.1016/j.expneurol.2015.05.013
Ferreira, G. K., Carvalho-Silva, M., Gomes, L. M., Scaini, G., Teixeira, L. J.,
Mota, I. T., et al. (2015). The characterization of neuroenergetic effects
of chronic L-tyrosine administration in young rats: evidence for striatal
susceptibility. Metab. Brain Dis. 30, 215–221. doi: 10.1007/s11011-014-
9615-3
Ferreira, G. K., Carvalho-Silva, M., Gonçalves, C. L., Vieira, J. S., Scaini, G.,
Ghedim, F. V., et al. (2012). L-tyrosine administration increases
acetylcholinesterase activity in rats. Neurochem. Int. 61, 1370–1374.
doi: 10.1016/j.neuint.2012.09.017
Finelli, A., Kelkar, A., Song, H.-J., Yang, H., and Konsolaki, M. (2004). Amodel for
studying Alzheimer’s Aβ42-induced toxicity in Drosophila melanogaster. Mol.
Cell. Neurosci. 26, 365–375. doi: 10.1016/j.mcn.2004.03.001
Gallant, M., Rak, M., Szeghalmi, A., Del Bigio, M. R., Westaway, D., Yang, J., et al.
(2006). Focally elevated creatine detected in amyloid precursor protein (APP)
transgenic mice and Alzheimer disease brain tissue. J. Biol. Chem. 281, 5–8.
doi: 10.1074/jbc.C500244200
Gargano, J. W., Martin, I., Bhandari, P., and Grotewiel, M. S. (2005). Rapid
iterative negative geotaxis (RING): a new method for assessing age-related
locomotor decline in Drosophila. Exp. Gerontol. 40, 386–395. doi: 10.1016/j.
exger.2005.02.005
Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N., and Nakayama, K. I. (2001).
U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276,
33111–33120. doi: 10.1074/jbc.m102755200
Hegele, A., Kamburov, A., Grossmann, A., Sourlis, C., Wowro, S., Weimann, M.,
et al. (2012). Dynamic protein-protein interaction wiring of the
human spliceosome. Mol. Cell 45, 567–580. doi: 10.1016/j.molcel.2011.
12.034
Jackson, G. R. (2008). Guide to understanding Drosophila models of
neurodegenerative diseases. PLoS Biol. 6:e53. doi: 10.1371/journal.pbio.
0060053
Kandimalla, R. J. L., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Gupta, N.,
Sharma, D. R., et al. (2011). Apo-E4 allele in conjunction with Aβ42 and tau
Frontiers in Aging Neuroscience | www.frontiersin.org 12 March 2017 | Volume 9 | Article 61
Belfiori-Carrasco et al. Genetic Screen for Aβ Modifiers
in CSF: biomarker for Alzheimers disease. Curr. Alzheimer Res. 8, 187–196.
doi: 10.2174/156720511795256071
Kandimalla, R. J. L., Wani, W. Y., Binukumar, B. K., and Gill, K. D. (2012). siRNA
against presenilin 1 (PS1) down regulates amyloid β42 production in IMR-32
cells. J. Biomed. Sci. 19:2. doi: 10.1186/1423-0127-19-2
Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade
hypothesis for Alzheimer’s disease: an appraisal for the development of
therapeutics. Nat. Rev. Drug Discov. 10, 698–712. doi: 10.1038/nrd3505
Khan, S., and Bloom, G. S. (2016). Tau: the center of a signaling nexus in
Alzheimer’s disease. Front. Neurosci. 10:31. doi: 10.3389/fnins.2016.00031
Lenz, S., Karsten, P., Schulz, J. B., and Voigt, A. (2013). Drosophila as a screening
tool to study human neurodegenerative diseases. J. Neurochem. 127, 453–460.
doi: 10.1111/jnc.12446
Lim, J. Y., Ott, S., and Crowther, D. C. (2016). Drosophila melanogaster as a model
for studies on the early stages of Alzheimer’s disease.Methods Mol. Biol. 1303,
227–239. doi: 10.1007/978-1-4939-2627-5_13
Liu, H., Han, M., Li, Q., Zhang, X., Wang, W. A., and Huang, F. D. (2015).
Automated rapid iterative negative geotaxis assay and its use in a genetic screen
for modifiers of Aβ42-induced locomotor decline inDrosophila.Neurosci. Bull.
31, 541–549. doi: 10.1007/s12264-014-1526-0
Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Walker, D. G., Hunter, J. M.,
Kruchowsky, J. C., et al. (2011). Alzheimer’s disease and non-demented high
pathology control nonagenarians: comparing and contrasting the biochemistry
of cognitively successful aging. PLoS One 6:e27291. doi: 10.1371/journal.pone.
0027291
Martinez, M., Frank, A., Diez-Tejedor, E., and Hernanz, A. (1993). Amino
acid concentrations in cerebrospinal fluid and serum in Alzheimer’s disease
and vascular dementia. J. Neural Transm. Park. Dis. Dement. Sect. 6, 1–9.
doi: 10.1007/bf02252617
Masurel-Paulet, A., Poggi-Bach, J., Rolland, M. O., Bernard, O., Guffon, N.,
Dobbelaere, D., et al. (2008). NTBC treatment in tyrosinaemia type I:
long-term outcome in French patients. J. Inherit. Metab. Dis. 31, 81–87.
doi: 10.1007/s10545-008-0793-1
Mayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O.,
van Spronsen, F., et al. (2014). Cross-sectional study of 168 patients with
hepatorenal tyrosinaemia and implications for clinical practice. Orphanet.
J. Rare Dis. 9:107. doi: 10.1186/s13023-014-0107-7
Meyer, L. E., Machado, L. B., Santiago, A. P., da-Silva, W. S., De Felice, F. G.,
Holub, O., et al. (2006). Mitochondrial creatine kinase activity prevents reactive
oxygen species generation: antioxidant role of mitochondrial kinase-dependent
ADP re-cycling activity. J. Biol. Chem. 281, 37361–37371. doi: 10.1074/jbc.
m604123200
Moloney, A., Sattelle, D. B., Lomas, D. A., and Crowther, D. C. (2010). Alzheimer’s
disease: insights fromDrosophilamelanogastermodels.Trends Biochem. Sci. 35,
228–235. doi: 10.1016/j.tibs.2009.11.004
Moran, M. T., Tare, M., Kango-Singh, M., and Singh, C. (2013). Homeotic
gene teashirt (tsh) has a neuroprotective function in amyloid-β 42 mediated
neurodegeneration. PLoS One 8:e80829. doi: 10.1371/journal.pone.0080829
Newman, M., Musgrave, I. F., Musgrave, F. I., and Lardelli, M. (2007). Alzheimer
disease: amyloidogenesis, the presenilins and animal models. Biochim. Biophys.
Acta 1772, 285–297. doi: 10.1016/j.bbadis.2006.12.001
Perez-Nievas, B. G., Stein, T. D., Tai, H. C., Dols-Icardo, O., Scotton, T. C.,
Barroeta-Espar, I., et al. (2013). Dissecting phenotypic traits linked
to human resilience to Alzheimer’s pathology. Brain 136, 2510–2526.
doi: 10.1093/brain/awt171
Prüßing, K., Voigt, A., and Schulz, J. B. (2013). Drosophila melanogaster as
a model organism for Alzheimer’s disease. Mol. Neurodegener. 35, 1–11.
doi: 10.1186/1750-1326-8-35
Pushkarsky, T., Yurchenko, V., Vanpouille, C., Brichacek, B., Vaisman, I.,
Hatakeyama, S., et al. (2005). Cell surface expression of CD147/EMMPRIN is
regulated by cyclophilin 60. J. Biol. Chem. 280, 27866–27871. doi: 10.1074/jbc.
M503770200
Rival, T., Page, R. M., Chandraratna, D. S., Sendall, T. J., Ryder, E.,
Liu, B., et al. (2009). Fenton chemistry and oxidative stress mediate the
toxicity of the β-amyloid peptide in a Drosophila model of Alzheimer’s
disease. Eur. J. Neurosci. 29, 1335–1347. doi: 10.1111/j.1460-9568.2009.
06701.x
Sarantseva, S., Timoshenko, S., Bolshakova, O., Karaseva, E., Rodin, D.,
Schwarzman, A. L., et al. (2009). Apolipoprotein E-mimetics inhibit
neurodegeneration and restore cognitive functions in a transgenic Drosophila
model of Alzheimer’s disease. PLoS One 4:e8191. doi: 10.1371/journal.pone.
0008191
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B.,
Salloway, S., et al. (2016). Alzheimer’s disease. Lancet 338, 505–517.
doi: 10.1016/s0140-6736(15)01124-1
Scott, C. R. (2006). The genetic tyrosinemias. Am. J. Med. Genet. C Semin. Med.
Genet. 142C, 121–126. doi: 10.1007/978-1-4614-6430-3_279-1
Shulman, J. M., Imboywa, S., Giagtzoglou, N., Powers, M. P., Hu, Y.,
Devenport, D., et al. (2014). Functional screening in Drosophila identifies
Alzheimer’s disease susceptibility genes and implicates Tau-mediated
mechanisms. Hum. Mol. Genet. 23, 870–877. doi: 10.1093/hmg/
ddt478
Skalsky, Y. M., Ajuh, P. M., Parker, C., Lamond, A. I., Goodwin, G., and
Cooper, C. S. (2001). PRCC, the commonest TFE3 fusion partner in papillary
renal carcinoma is associated with pre-mRNA splicing factors. Oncogene. 20,
178–187. doi: 10.1038/sj.onc.1204056
Steffener, J., and Stern, Y. (2012). Exploring the neural basis of cognitive reserve
in aging. Biochim. Biophys. Acta 1822, 467–473. doi: 10.1016/j.bbadis.2011.
09.012
Tan, L., Schedl, P., Song, H.-J., Garza, D., and Konsolaki, M. (2008). The
toll→NFkB signaling pathway mediates the neuropathological effects of the
human Alzheimer’s Aβ42 Polypeptide in Drosophila. PLoS One. 3:e3966.
doi: 10.1371/journal.pone.0003966
Thimm, E., Richter-Werkle, R., Kamp, G., Molke, B., Herebian, D., Klee, D.,
et al. (2012). Neurocognitive outcome in patients with hypertyrosinemia type
I after long-term treatment with NTBC. J. Inherit. Metab. Dis. 35, 263–268.
doi: 10.1007/s10545-011-9394-5
Wallimann, T., Tokarska-Schlattner, M., and Schlattner, U. (2011). The creatine
kinase system and pleiotropic effects of creatine. Amino Acids 40, 1271–1296.
doi: 10.1007/s00726-011-0877-3
Zeybek, A. C., Kiykim, E., Soyucen, E., Cansever, S., Altay, S., Zubarioglu, T.,
et al. (2015). Hereditary tyrosinemia type 1 in Turkey: twenty year
single-center experience. Pediatr. Int. 57, 281–289. doi: 10.1111/ped.
12503
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Belfiori-Carrasco, Marcora, Bocai, Ceriani, Morelli and Castaño.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution and reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 13 March 2017 | Volume 9 | Article 61
